ACTRN12612000087853
Recruiting
未知
Patient outcome after reversal of residual neuromuscular blockade with either neostigmine or no reversal agent vs. reversal with sugammadex.
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Residual neuromuscular blockade, its reversal and associated patient outcome
- Sponsor
- Thomas Ledowski
- Enrollment
- 1600
- Status
- Recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients operated at Royal Perth Hospital and tracheally intubated with the use of a neuromuscular blocking agent. Hereby the reason for the operation (\= original medical condition leading to treatment) is unimportant
Exclusion Criteria
- •Patients with significant multi\-trauma, cardiothoracic surgery and patients who arrive in or leave theatres intubated
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Clinical and radiological outcoume following reverse shoulder arthroplasty in fracturesOutcome of reverse shoulder arthroplasty after fracturesDRKS00026227BG Unfallklinik Tübingen62
Not yet recruiting
Not Applicable
A study to assess inadequate neuromuscular recovery in postoperative period immediately on arrival and after 30 minutes of arrival by measuring Train of Four ratios after use of intermediate muscle relaxant intraoperativelyHealth Condition 1: O- Medical and SurgicalCTRI/2023/09/057759Max Superspeciality Hospital
Completed
Not Applicable
The outcome and prognosis of neurological decompression and stabilization for spinal metastasisspinal metastasisJPRN-UMIN000029381Department of Orthopaedic Surgery Yokosuka Kyosai Hospital30
Completed
Not Applicable
ong-term clinical outcome after reconstruction of atrophied alveolar ridge using collagenated xenogeneic bone block (CXBB) or autogenous bone block (ABB). Follow-up of randomized controlled clinical investigation 10828-021.Survival of the implants as well as the bone tissue and soft tissue at the augmented areaDRKS00017137Geistlich Pharma AG51
Completed
Phase 1
Outcomes of care for patients with residual symptoms of COVID-19 infection with lifestyle medicine and integrative medicinePost COVID-19 syndromeCOVID-19, integrative medicine, post-COVID syndrome, lifestyle medicineTCTR20230314001Chao Phya Abhaibhubejhr hospital foundation20